No Data
KINGWORLD: Interim Report 2024
Kingworld Pharmaceutical Group (01110): Chu Xiaoping appointed as an independent non-executive director
Kingworld (01110) announced that Dr. Chu Xiaoping has been appointed as an independent non-executive director, nomination committee,...
Kingworld Appoints New Independent Director
Kingworld Medicines Unveils New Board Structure
Jinhuo Medicine (01110.HK) is innovating and creating a new engine.
With the approaching of the expectation of interest rate cuts by the Federal Reserve and the increase of policy support, the pharmaceutical sector, with its low valuation and high cost-effectiveness, has become a focus area of the market's attention. Several brokerages have predicted that after the mid-term report is released, negative factors within the pharmaceutical industry will be effectively digested, indicating that the second half of the year will be a golden opportunity to layout in this sector. Of particular interest is the recent release of the performance of Kingworld Pharmaceutical Group Co., Ltd. (referred to as 'Kingworld Pharmaceutical') for the first half of 2024, which has demonstrated strong resilience and stabilized the company's foundation in the industry's overall downturn environment. The company has long been deeply rooted in the pharmaceutical market and has a portfolio that includes domestic products.
In terms of performance, China Jinhao Pharmaceuticals (01110.HK) reported a mid-year net profit of 30.72 million RMB, a decrease of 18.6% with no dividend payment.
Kingworld (01110.HK) announced its interim performance for the six months ending in June, with a revenue of 0.526 billion RMB, a year-on-year decrease of 4.9%. Net profit was recorded at 30.72 million yuan, a decline of 18.6%, with earnings per share of 5.2 fen. No interim dividend will be distributed.
No Data
No Data